Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of add-on doxofylline on symptom improvement in severe COPD exacerbation
TCTR20250217001Phase 0Unknown
- Start
- Apr 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 0 trial of doxofylline in chronic obstructive pulmonary disease exacerbation, sponsored by none. Primary endpoint: Symptom improvement during severe COPD exacerbation. Status: unknown.
02
Drugs
doxofylline
03
Conditions
chronic obstructive pulmonary disease exacerbation
Beyond the preview
Go deeper on TCTR20250217001.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on TCTR20250217001.